http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Jul 2026 16:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kailera+Therapeutics%2C+++++For%3A+Jul+06++Filed+by%3A+Tregoning+Kathleen/26747819.html si-local-file:///var/storage/secattach/20260708/26747819.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kailera+Therapeutics%2C+++++For%3A+Jul+06++Filed+by%3A+Tregoning+Kathleen/26747819.html Wed, 08 Jul 2026 16:20:00 -0400 KLRA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Kailera+Therapeutics%2C+++++For%3A+Jun+29++Filed+by%3A+Tregoning+Kathleen/26747738.html si-local-file:///var/storage/secattach/20260708/26747738.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Kailera+Therapeutics%2C+++++For%3A+Jun+29++Filed+by%3A+Tregoning+Kathleen/26747738.html Wed, 08 Jul 2026 16:15:00 -0400 KLRA http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Press+Releases/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html <p>WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.</p> <p>“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new http://www.streetinsider.com/Globe+Newswire/Kailera+Therapeutics+Appoints+Kathleen%C2%A0Tregoning+as+Chief+Corporate+Affairs+Officer/26702099.html Mon, 29 Jun 2026 07:30:00 -0400 A.11608963 A.34618214 CMPS KLRA O.05010326 O.30518154 O.35865569 O.47928049 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kailera+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+Renaud+Ronald+C+JR/26635593.html si-local-file:///var/storage/secattach/20260611/26635593.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kailera+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+Renaud+Ronald+C+JR/26635593.html Thu, 11 Jun 2026 16:05:00 -0400 KLRA http://www.streetinsider.com/Press+Releases/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html <ul type="disc"><li><em>Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight</em></li><li><em>Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with </em><em>v</em><em>omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively</em></li><li><em>Phase 1 single ascending dose trial, the first http://www.streetinsider.com/Press+Releases/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html Fri, 05 Jun 2026 19:32:00 -0400 A.20822773 KLRA O.20370956 http://www.streetinsider.com/Press+Releases/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html <ul type="disc"><li><em>Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight</em></li><li><em>Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with </em><em>v</em><em>omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively</em></li><li><em>Phase 1 single ascending dose trial, the first http://www.streetinsider.com/Press+Releases/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html Fri, 05 Jun 2026 19:32:00 -0400 A.20822773 KLRA O.20370956 http://www.streetinsider.com/Press+Releases/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html <ul type="disc"><li><em>Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight</em></li><li><em>Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with </em><em>v</em><em>omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively</em></li><li><em>Phase 1 single ascending dose trial, the first http://www.streetinsider.com/Press+Releases/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html Fri, 05 Jun 2026 19:32:00 -0400 A.20822773 KLRA O.20370956 http://www.streetinsider.com/Globe+Newswire/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html <ul type="disc"><li><em>Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight</em></li><li><em>Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with </em><em>v</em><em>omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively</em></li><li><em>Phase 1 single ascending dose trial, the first http://www.streetinsider.com/Globe+Newswire/Hengrui+Pharma+and+Kailera+Therapeutics+Present+Ribupatide+Clinical+Data+at+ADA+2026/26612613.html Fri, 05 Jun 2026 19:32:00 -0400 A.20822773 KLRA O.20370956